A Combined Method Based on the FIPV N Monoclonal Antibody Immunofluorescence Assay and RT-nPCR Method for the Rapid Diagnosis of FIP-Suspected Ascites

Figure 2

(a) Identification of the amplified products of the FIPV BS8 N gene. Lane 1, FIPV BS8 N, lane M DL2000 marker. (b) Identification of the expressed and purified products of FIPV BS8 N recombination protein by SDS‒PAGE, lane M, protein marker; lane 1, pMAL-C5X–BS8-N with IPTC; lane 2, pMAL-C5X–BS8-N expression product purified by affinity chromatography; lane 3, purified pMAL-C5X–BS8-N protein cleaved by Xa Factor; lane 4, GE HiTrap Q FF purified pMAL-C5X–BS8-N protein without MBP. (c) Identification of the expressed and purified products of the FIPV BS8 N recombination protein by Western blotting. Lane M protein marker; lane 1, purified pMAL-C5X–BS8-N protein. (d) Mouse serum titers after booster immunization. Serially diluted serum samples were tested using an indirect ELISA, and serum samples from unimmunized mice served as the negative control.

(a)

(b)

(c)

(d)